NEW YORK (GenomeWeb) – HTG Molecular Diagnostics is out of compliance with a Nasdaq listing requirement, the firm said in a document filed with the US Securities and Exchange Commission on Friday.

The company said that it was notified by Nasdaq on July 31 that the market value of its listed securities did not meet the exchange's minimum standard of at least $35 million for the past 30 consecutive trading days. HTG has until Jan. 29, 2018 to regain compliance by meeting the $35 million requirement for at least 10 consecutive business days.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

An opinion piece in the Guardian argues that President Donald Trump is uninterested in science and that might not be a bad thing for the field.

The San Francisco Chronicle reports the Veterans Affairs Health System is studying whether genetic testing can help prescribe better depression therapies.

Stat News reports that Spark Therapeutics' Luxturna is now being used to treat a wider array of patients.

In Genome Biology this week: transcription factor use among brittle stars, single-cell RNA sequencing strategy, and more.